Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2017 from OUS - Department of Urology
12 publications found
Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
Urology, 110, 140-147
Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations
BMC Urol, 17 (1), 111
Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer
Int J Oncol, 51 (1), 223-234
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
Asymptomatic bacteriuria, to screen or not to screen - and when to treat?
Curr Opin Urol, 27 (2), 107-111
The role of nutraceuticals and phytotherapy in the management of urinary tract infections: What we need to know?
Arch Ital Urol Androl, 89 (1), 1-6
Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium
J Alzheimers Dis, 55 (1), 371-379
MtDNA depletion influences the transition of CD44 subtypes in human prostate cancer DU145 cells
Tumour Biol, 39 (8), 1010428317713671
Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells
Oncotarget, 8 (28), 46363-46380
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Sci Rep, 7 (1), 5081
A Head-to-Head Comparative Phase II Study of Standard Urine Culture and Sensitivity Versus DNA Next-generation Sequencing Testing for Urinary Tract Infections
Rev Urol, 19 (4), 213-220
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology
Eur Urol, 72 (4), 509-518